BRPI0913425A2 - formulações de niacina com liberação modificada - Google Patents

formulações de niacina com liberação modificada

Info

Publication number: BRPI0913425A2
Authority: BR; Brazil
Prior art keywords: modified release; release niacin; niacin formulations; formulations; modified
Prior art date: 2008-06-02

Application number

BRPI0913425A

Other languages

English (en)

Inventor

Dhanajay Singare

Harshal Prabhakar Bhagwatwar

Ish Kumar Khanna

Pradeep Jairao Karatgi

Rajesh Vooturi

Raviraj Sukumar Pillai

Shantanu Yeshwant Damle

Sesha Sai Marella

Original Assignee

Reddys Lab Ltd Dr

Reddys Lab Inc Dr

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-02

Filing date

2009-06-02

Publication date

2015-11-24

2009-06-02 Application filed by Reddys Lab Ltd Dr, Reddys Lab Inc Dr filed Critical Reddys Lab Ltd Dr

2015-11-24 Publication of BRPI0913425A2 publication Critical patent/BRPI0913425A2/pt

Links

PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
229960003512 nicotinic acid Drugs 0.000 title 1
235000001968 nicotinic acid Nutrition 0.000 title 1
239000011664 nicotinic acid Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Pyridine Compounds (AREA)

BRPI0913425A 2008-06-02 2009-06-02 formulações de niacina com liberação modificada BRPI0913425A2 (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
IN1345CH2008		2008-06-02
US9416108P	2008-09-04	2008-09-04
IN1145CH2009		2009-05-18
PCT/US2009/045927 WO2009149058A2 (en)	2008-06-02	2009-06-02	Modified release niacin formulations

Publications (1)

Publication Number	Publication Date
BRPI0913425A2 true BRPI0913425A2 (pt)	2015-11-24

Family

ID=41398815

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0913425A BRPI0913425A2 (pt)	2008-06-02	2009-06-02	formulações de niacina com liberação modificada

Country Status (10)

Country	Link
US (1)	US20110123575A1 (pt)
EP (1)	EP2296709A4 (pt)
JP (1)	JP2011521977A (pt)
KR (1)	KR20110011643A (pt)
CN (1)	CN102105171A (pt)
AU (1)	AU2009256394A1 (pt)
BR (1)	BRPI0913425A2 (pt)
MX (1)	MX2010013169A (pt)
TR (1)	TR201009949T1 (pt)
WO (1)	WO2009149058A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE46608E1 (en)	2009-09-01	2017-11-14	Catabasis Pharmaceuticals, Inc.	Fatty acid niacin conjugates and their uses
WO2011028689A1 (en)	2009-09-01	2011-03-10	Catabasis Pharmaceuticals, Inc.	Fatty acid niacin conjugates and their uses
EP2481411A1 (en) *	2011-01-27	2012-08-01	Ratiopharm GmbH	Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
ES2583132T3 (es) *	2011-09-16	2016-09-19	Purdue Pharma L.P.	Formulaciones de liberación inmediata resistentes a alteración
DK2861229T3 (da)	2012-06-15	2021-01-18	Conaris Res Institute Ag	Farmaceutisk sammensætning indeholdende nikotinsyre og/eller niko-tinamid og/eller tryptophan til positiv påvirkning af tarmmikrobiataen
WO2015086838A2 (en)	2013-12-13	2015-06-18	Conaris Research Institute Ag	A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
HUE048488T2 (hu) *	2013-12-13	2020-07-28	Conaris Res Institute Ag	Nikotinsavat és/vagy nikotinamidot tartalmazó gyógyászati készítmény a vérlipid szint jótékony hatású befolyására történõ alkalmazásra a bélrendszeri mikrobióta módosításával
US20220193033A1 (en) *	2019-04-30	2022-06-23	Dsm Ip Assets B.V.	New delivery system for specific water-soluble vitamins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5126145A (en) *	1989-04-13	1992-06-30	Upsher Smith Laboratories Inc	Controlled release tablet containing water soluble medicament
US5268181A (en) *	1989-04-13	1993-12-07	Upsher-Smith Laboratories, Inc.	Method of using niacin to control nocturnal cholesterol synthesis
US6676967B1 (en) *	1993-09-20	2004-01-13	Kos Pharmaceuticals, Inc.	Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6129930A (en) *	1993-09-20	2000-10-10	Bova; David J.	Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6818229B1 (en) *	1993-09-20	2004-11-16	Kos Pharmaceuticals, Inc.	Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6746691B2 (en) *	1993-09-20	2004-06-08	Kos Pharmaceuticals, Inc.	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6406715B1 (en) *	1993-09-20	2002-06-18	Kos Pharmaceuticals, Inc.	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles
US6080428A (en) *	1993-09-20	2000-06-27	Bova; David J.	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
AU5787996A (en) *	1995-04-19	1996-11-07	Lipoprotein Technologies, Inc.	Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
US7179486B1 (en) *	1997-04-01	2007-02-20	Nostrum Pharmaceuticals, Inc.	Process for preparing sustained release tablets
EP1792616B1 (en) *	1997-07-31	2009-12-16	Abbott Respiratory LLC	Composition comprising an HMG-CoA inhibitor and a nicotinic acid compound for treating hyperlipidemia
US6469035B1 (en) *	1997-07-31	2002-10-22	Eugenio A. Cefali	Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
US7985422B2 (en) *	2002-08-05	2011-07-26	Torrent Pharmaceuticals Limited	Dosage form
US8216609B2 (en) *	2002-08-05	2012-07-10	Torrent Pharmaceuticals Limited	Modified release composition of highly soluble drugs
EP1589951B1 (en) *	2003-01-03	2017-08-09	Supernus Pharmaceuticals, Inc.	Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
US20050058688A1 (en) *	2003-02-22	2005-03-17	Lars Boerger	Device for the treatment and prevention of disease, and methods related thereto
WO2005041878A2 (en) *	2003-10-29	2005-05-12	Tawakol Raif M D	Compositions and methods for increasing hdl and hdl-2b levels
ES2545589T3 (es) *	2005-04-08	2015-09-14	Abbott Laboratories	Formulaciones farmacéuticas orales que comprenden sales de ácido fenofíbrico
CA2569776A1 (en) *	2006-02-17	2007-08-17	Kos Life Sciences, Inc.	Low flush niacin formulation

2009
- 2009-06-02 US US12/995,718 patent/US20110123575A1/en not_active Abandoned
- 2009-06-02 TR TR2010/09949T patent/TR201009949T1/xx unknown
- 2009-06-02 WO PCT/US2009/045927 patent/WO2009149058A2/en not_active Ceased
- 2009-06-02 EP EP09759219A patent/EP2296709A4/en not_active Withdrawn
- 2009-06-02 KR KR1020107026615A patent/KR20110011643A/ko not_active Withdrawn
- 2009-06-02 AU AU2009256394A patent/AU2009256394A1/en not_active Abandoned
- 2009-06-02 BR BRPI0913425A patent/BRPI0913425A2/pt not_active Application Discontinuation
- 2009-06-02 MX MX2010013169A patent/MX2010013169A/es not_active Application Discontinuation
- 2009-06-02 JP JP2011511900A patent/JP2011521977A/ja not_active Withdrawn
- 2009-06-02 CN CN2009801295002A patent/CN102105171A/zh active Pending

Also Published As

Publication number	Publication date
TR201009949T1 (tr)	2011-03-21
MX2010013169A (es)	2010-12-21
EP2296709A4 (en)	2012-02-01
WO2009149058A2 (en)	2009-12-10
EP2296709A2 (en)	2011-03-23
AU2009256394A1 (en)	2009-12-10
US20110123575A1 (en)	2011-05-26
WO2009149058A8 (en)	2010-07-15
KR20110011643A (ko)	2011-02-08
CN102105171A (zh)	2011-06-22
JP2011521977A (ja)	2011-07-28
WO2009149058A3 (en)	2010-02-25

Legal Events

Date	Code	Title	Description
2016-04-12	B11A	Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
2016-07-26	B11Y	Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired

Publication	Publication Date	Title
BRPI0914630A2 (pt)	2019-09-24	liberação dérmica
BRPI0907884A2 (pt)	2015-07-21	Partícula de liberação
BRPI0909220A2 (pt)	2015-08-25	Partícula de liberação
BRPI0818874A2 (pt)	2015-05-05	Liberação de agentes ativos
BRPI0916612A2 (pt)	2015-11-10	partícula de liberação
BRPI0921327A2 (pt)	2015-08-25	Combinação de herbicida-protetor
BRPI0906749A2 (pt)	2015-07-07	Composição
BRPI0913808A2 (pt)	2017-06-20	composição
BRPI0918652A2 (pt)	2015-08-25	Composições farmacêuticas e métodos de libração relacionadas.
DK2340021T3 (da)	2012-12-10	Substituerede pyrrolidin-2-carboxamider
EP2381760A4 (en)	2013-01-16	CORN PROTEIN COMPOSITION
BRPI0922480A2 (pt)	2018-06-05	compósitos de nanocalcita
FIC20240018I1 (fi)	2024-06-04	Vamoroloni
BRPI0814188A2 (pt)	2014-10-14	Formulações
BRPI0917231A2 (pt)	2015-11-10	composição
IT1392101B1 (it)	2012-02-09	Composizione comprendente isoflavoni
BRPI0908114A2 (pt)	2015-10-06	tabuleta oral de liberação controlada
BRPI0907122A2 (pt)	2015-07-14	Piridoindóis (1-azinona) substituídos
BRPI0922423A2 (pt)	2015-12-15	dispositivo de liberação de fármaco
BRPI0917673A2 (pt)	2015-08-18	Combinação de herbicida-protetor compreendendo difluorometanossulfonilanilidas substituidas por dimetoxitriazinila
DK2278899T3 (da)	2012-11-26	Bryggemekanisme
BRPI0913425A2 (pt)	2015-11-24	formulações de niacina com liberação modificada
BRPI0922728A2 (pt)	2019-09-24	combinação de herbicida-antídoto
BRPI0811732A2 (pt)	2014-11-18	Formulação de liberação prolongada de nevirapina
EP2357204A4 (en)	2012-06-27	COMPOSITION